AU2017379082A1 - Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide - Google Patents

Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide Download PDF

Info

Publication number
AU2017379082A1
AU2017379082A1 AU2017379082A AU2017379082A AU2017379082A1 AU 2017379082 A1 AU2017379082 A1 AU 2017379082A1 AU 2017379082 A AU2017379082 A AU 2017379082A AU 2017379082 A AU2017379082 A AU 2017379082A AU 2017379082 A1 AU2017379082 A1 AU 2017379082A1
Authority
AU
Australia
Prior art keywords
linaclotide
week
baseline
pain
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2017379082A
Other languages
English (en)
Inventor
Ahmad Hashash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of AU2017379082A1 publication Critical patent/AU2017379082A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017379082A 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide Pending AU2017379082A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437566P 2016-12-21 2016-12-21
US62/437,566 2016-12-21
PCT/US2017/067814 WO2018119191A1 (en) 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Publications (1)

Publication Number Publication Date
AU2017379082A1 true AU2017379082A1 (en) 2019-07-04

Family

ID=61022424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017379082A Pending AU2017379082A1 (en) 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Country Status (10)

Country Link
EP (1) EP3558337A1 (zh)
JP (2) JP2020512292A (zh)
CN (1) CN110475564A (zh)
AU (1) AU2017379082A1 (zh)
BR (1) BR112019012689A2 (zh)
CA (1) CA3048195A1 (zh)
EA (1) EA201991531A1 (zh)
MA (1) MA47112A (zh)
MX (2) MX2019007574A (zh)
WO (1) WO2018119191A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979992A4 (en) * 2019-06-10 2023-09-13 Ironwood Pharmaceuticals, Inc. TREATMENT OF ABDOMINAL PAIN ASSOCIATED WITH DIARRHEA-DOMINANT IRGITABLE BOWEL SYSTEM
CA3238619A1 (en) * 2021-11-29 2023-06-01 Michael Gerber Pharmaceutical compositions for the treatment of visceral pain
WO2023196821A2 (en) * 2022-04-04 2023-10-12 Thomas Jefferson University Targeting neuropod cell gucy2c to control visceral pain and appetite

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
HUE049023T2 (hu) 2008-08-15 2020-08-28 Ironwood Pharmaceuticals Inc Linaklotidot tartalmazó, szájon át történõ beadásra szolgáló készítmények
WO2011020054A1 (en) * 2009-08-13 2011-02-17 Ironwood Pharmaceuticals Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
RS59978B1 (sr) * 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
DK2776055T3 (en) * 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
CA2898362C (en) * 2013-01-15 2020-09-01 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
ES2868873T3 (es) * 2015-06-05 2021-10-22 Ironwood Pharmaceuticals Inc Formulaciones de liberación modificada o dirigida de linaclotida

Also Published As

Publication number Publication date
CN110475564A (zh) 2019-11-19
WO2018119191A1 (en) 2018-06-28
JP2020512292A (ja) 2020-04-23
CA3048195A1 (en) 2018-06-28
MA47112A (fr) 2019-10-30
EP3558337A1 (en) 2019-10-30
BR112019012689A2 (pt) 2019-11-19
MX2019007574A (es) 2019-09-04
JP2022093472A (ja) 2022-06-23
EA201991531A1 (ru) 2019-11-29
MX2023008839A (es) 2023-08-14
WO2018119191A9 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
AU2020202319B2 (en) Delayed release compositions of linaclotide
JP2022093472A (ja) リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法
US20220202725A1 (en) Modified or Targeted Release Formulations of Linaclotide
US20230346878A1 (en) Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
US20230142270A1 (en) Delayed Release Compositions of Linaclotide
BR112016013419B1 (pt) Composições de liberação retardada compreendendo um comprimido com revestimento entérico, forma de dosagem unitária e uso